OCUL

Announcements

Nothing here yet

Daily updates

• Ocular Therapeutix shares declined significantly following wet AMD updates from Kodiak Sciences and 4D Molecular Therapeutics, increasing competitive pressure in sustained-release ophthalmology.Sep 29, 2026

FDA designations

Nothing here yet

News

• Ocular Therapeutix announced a positive pre-NDA meeting with the U.S. FDA for AXPAXLI in wet AMDSep 15, 2026
• Ocular Therapeutix enrolled the first patient in the SOL-X long-term extension trial for AXPAXLI in wet AMDApr 29, 2026
• Ocular Therapeutix reported additional positive 52-week data from Phase 3 SOL-1 trial of AXPAXLIApr 13, 2026
• Ocular Therapeutix announces plans to accelerate NDA submission for AXPAXLI™ in wet AMDDec 8, 2025
• Ocular Therapeutix™ announced first patient randomized in HELIOS-3 Phase 3 registrational program for AXPAXLI™ in non-proliferative diabetic retinopathyNov 24, 2025